/

CEL-SCI Corporation

LSRM GS

LSRM GSCEL-SCI Corporation

STUTTGART

1.11

EUR

-0.01

(-0.89%)

Next Earnings

August 11

Ex-Dividend Date

August 28

Dividend Date

June 15

Held by Insiders

3.61%

Held by Institutions

11.94%

Short % of Float

11.79%

YTD Yield

-59.12%

3Y Yield

-88.43%

Capital Structure

FRC

•

in mil. unless spec.

ST Debt

LT Borrowings

LT Finance Leases

Preferred Equity and Hybrid Capital

Shares Outstanding

Market Capitalization

Working Capital

FRC

•

in mil. unless spec.

Total Current Assets

Cash, Cash Equivalents & STI

Accounts Receivable, Net

Inventories

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

- -

Net Income, GAAP

- -

Free Cash Flow

- -

Total Cash Common Dividend

- -

Total Equity

- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

-Infinity

- -

-Infinity

- -

-Infinity

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

-Infinity

- -

-Infinity

- -

-Infinity

- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

-Infinity

- -

-Infinity

- -

-Infinity

- -

Company Description

Sector: Healthcare
Industry: Biotechnology
Address: 8229 Boone Boulevard Vienna VA United States 22182
CIK: 0000725363
Website: cel-sci.com
Business: CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Company News

Dow Jones Newswires
2 months ago
Syncona Portfolio Company to Present Updated Data on Cancer Study
Dow Jones Newswires
4 months ago
CEL-SCI 3Q Loss/Shr 19c >CVM
Dow Jones Newswires
7 months ago
CEL-SCI 2Q Loss/Shr 19c >CVM
Dow Jones Newswires
7 months ago
CEL-SCI Shares Rise 14% After Meeting With Health Canada About Multikine

Company Description

Sector: Healthcare
Industry: Biotechnology
Address: 8229 Boone Boulevard Vienna VA United States 22182
CIK: 0000725363
Website: cel-sci.com
Business: CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.